Michael Hwang, MD
Head and Neck Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Head and Neck Cancer
- Salivary Gland Cancer
- Thyroid Cancer
Request an Appointment
About Me
- Assistant Attending Physician
I am a board-certified medical oncologist specializing in the care of patients with head and neck cancer. My father’s experience with head and neck cancer inspired me to enter the field of medicine. After witnessing how his oncologist not only formulated a treatment plan for him, but also addressed all his concerns with patience, compassion, and understanding, I knew I wanted to pursue a career in oncology.
As a physician at Memorial Sloan Kettering Commack and Memorial Sloan Kettering Nassau, I deliver cancer care to the central and eastern Long Island community. I am focused on providing innovative, evidence-based care and bringing clinical trials closer to patients’ homes and communities.
Read more
I am thankful for the opportunity to provide high-quality care for patients with cancer and to develop a personalized treatment plan for each patient through both standard and emerging approaches. Each patient’s journey with cancer is unique; I work to walk alongside my patients and their caregivers, giving support and guidance from the time of diagnosis through treatment and beyond.
I completed my undergraduate studies in biology at Cornell University, my MD at Rutgers New Jersey Medical School, my residency in internal medicine at the Icahn School of Medicine at Mount Sinai Hospital, and my fellowship in medical oncology at the Sidney Kimmel Comprehensive Cancer Center of the Johns Hopkins School of Medicine. Prior to joining MSK, I was an Assistant Professor in the Upper Aerodigestive Department at Johns Hopkins Hospital, specializing in the treatment of head and neck cancers.
A head and neck medical oncologist is a cancer doctor who specializes in head and neck cancers. This includes cancers of the larynx, lips, mouth, nose, salivary glands, and throat.
My Specialties
- Head and Neck Cancer
- Salivary Gland Cancer
- Thyroid Cancer
- Lung Cancer
Education
- MD, Rutgers New Jersey Medical School
Residencies
- Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital
Awards and Honors
- Scholar-in-Training Award, American Association for Cancer Research/Bristol Myers Squibb (2021)
- Science of Clinical Investigation Achievement Award, Johns Hopkins Hospital (2021)
- T32 Molecular Targets for Cancer Detection and Treatment Grant, Johns Hopkins Hospital (2020-2021)
Fellowships
- Medical Oncology, Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins School of Medicine
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Hwang sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, Reuss JE, Marrone K, Murray JC, Li QK, Lam V, Levy BP, Hann C, Velculescu VE, Brahmer JR, Forde PM, Seiwert T, Anagnostou V. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022 Jun;10(6):e004688. doi: 10.1136/jitc-2022-004688. PMID: 35688557; PMCID: PMC9189831.
Takahashi M, Hwang M, Misiukiewicz K, Gupta V, Miles BA, Bakst R, Genden E, Selkridge I, Botzler J, Virani V, Moshier E, Bonomi MR, Posner MR. Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up. Front Oncol. 2022 Apr 8;12:859992. doi: 10.3389/fonc.2022.859992. PMID: 35463348; PMCID: PMC9024140.
Misiukiewicz K, Gupta V, Miles BA, Bakst R, Genden E, Selkridge I, Surgeon JT, Rainey H, Camille N, Roy E, Zhang D, Ye F, Jia R, Moshier E, Bonomi M, Hwang M, Som P, Posner MR. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial. Oral Oncol. 2019 Aug;95:170-177. doi: 10.1016/j.oraloncology.2019.06.021. Epub 2019 Jun 25. PMID: 31345387.
Visit PubMed for a full listing of Dr. Hwang’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael Hwang discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].